Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Genomic Health, Inc.    GHDX

GENOMIC HEALTH, INC. (GHDX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/16/2018 04/17/2018 04/18/2018 04/19/2018 04/20/2018 Date
33.31(c) 32.75(c) 32.53(c) 32.2(c) 32.23(c) Last
191 005 234 318 80 337 70 289 58 770 Volume
+0.88% -1.68% -0.67% -1.01% +0.09% Change
More quotes
Financials (USD)
Sales 2018 373 M
EBIT 2018 16,3 M
Net income 2018 12,0 M
Finance 2018 129 M
Yield 2018 -
Sales 2019 414 M
EBIT 2019 30,9 M
Net income 2019 25,5 M
Finance 2019 177 M
Yield 2019 -
P/E ratio 2018 144,33
P/E ratio 2019 45,90
EV / Sales2018 2,70x
EV / Sales2019 2,32x
Capitalization 1 139 M
More Financials
Company
Genomic Health, Inc. provides genomic-based diagnostic tests, which analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions.It uses a platform which translates a massive amount of clinical and genomic data into clinically actionable... 
More about the company
Surperformance© ratings of Genomic Health, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on GENOMIC HEALTH, INC.
04/14GENOMIC HEALTH : Two Sigma Investments LP Sells 23,043 Shares of Genomic Health ..
AQ
04/02GENOMIC HEALTH : Epic Sciences and Genomic Health Announce Favorable Draft Local..
AQ
03/30GENOMIC HEALTH : Epic Sciences and Genomic Health Announce Favorable Draft Local..
PR
03/22ILLUMINA : Names Dr. Phil Febbo Chief Medical Officer
AQ
03/22GENOMIC HEALTH : Landmark TAILORx Results Aid in Assessing the Effect of Chemoth..
AQ
03/15GENOMIC HEALTH : Landmark TAILORx Results Aid in Assessing the Effect of Chemoth..
PR
03/14GENOMIC HEALTH : Management's Discussion and Analysis of Financial Condition and..
AQ
03/14BIOCENTURY - MANAGEMENT TRACKS : Ipsen, Illumina
AQ
03/08GENOMIC HEALTH : Results of Operations and Financial Condition, Financial Statem..
AQ
03/08GENOMIC HEALTH,INC. (NASDAQ : GHDX) Files An 8-K Results of Operations and Finan..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
11:37aKimberly J. Popovits Sells 15,000 Shares of Genomic Health $GHDX Stock  
04/19Kimberly J. Popovits Sells 15,000 Shares of Genomic Health $GHDX Stock  
04/18The President & CEO of Genomic Health (NASDAQ: GHDX) is Buying Shares $GH.. 
04/18$GHDX New SEC Document(s) for Genomic Health, Inc. From our Stock News Alerts.. 
04/13Two Sigma Investments LP Sells 23,043 Shares of Genomic Health $GHDX  
More tweets
Qtime:90
News from SeekingAlpha
04/02Epic Sciences and Genomic Health announces favorable draft LCD on medicare co.. 
03/08Genomic Health's (GHDX) CEO Kim Popovits on Q4 2017 Results - Earnings Call T.. 
03/08Genomic Health misses by $0.02, misses on revenue 
03/07Notable earnings before Thursday?s open 
03/06FDA OKs direct-to-consumer test for certain types of breast cancer mutations 
Chart GENOMIC HEALTH, INC.
Duration : Period :
Genomic Health, Inc. Technical Analysis Chart | GHDX | US37244C1018 | 4-Traders
Technical analysis trends GENOMIC HEALTH, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 32,4 $
Spread / Average Target 0,59%
EPS Revisions
Managers
NameTitle
Kimberly J. Popovits Chairman, President & Chief Executive Officer
Frederic G. Pla Chief Operating Officer
G. Bradley Cole Chief Financial Officer
Steven Shak Chief Medical & Scientific Officer
Michael Vedda Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
GENOMIC HEALTH, INC.-5.76%1 139
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258
LONZA GROUP-6.95%18 703
INCYTE CORPORATION-27.09%14 493
NEKTAR THERAPEUTICS44.36%13 873